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The economics of tackling climate change
Don’t leave health benefits out of the equation
Tony Blair welcomed the publication of the Stern 
review on the economics of climate change calling it a 
wake up call to the world.1 Its message was clear. The 
costs of taking action to stabilise the climate will be 
high but much less than the costs of inaction. Delay 
would be dangerous. Action is needed now. The review 
also exposed the economic cause of climate change. 
 Climate change is market failure on the greatest scale 
the world has ever seen.1
Markets fail to provide the right quantity of goods 
and services when important costs are left out of our 
private economic decision making. In general, the 
extent to which people engage in activities that result 
in the emission of greenhouse gases depends on the 
cost of those activities. For example, when deciding 
whether to travel by car we might consider the cost of 
the time, petrol, parking, and wear and tear on the vehi�
cle. Londoners might include the congestion charge, 
but few people would take into account the costs to 
the world and future generations of the emissions that 
their journey will produce. Costs on others that do not 
(without public action) enter into the private arithmetic 
of how we allocate resources are called externalities 
and are the economic basis of one of the greatest threats 
humanity has ever faced.
While economists have been grappling with the 
resource implications of policies to tackle climate 
change, the public health implications of these policies 
have also come under scrutiny.2 The message this time 
is that they present unrivalled opportunities for improv�
ing public health. Policies that reduce greenhouse gas 
emissions could also substantially reduce obesity, dia�
betes, heart disease, cancer, road deaths and injuries, 
and air pollution.2
Take food production for instance, which results in 
substantial greenhouse emissions, similar in magnitude 
to those from transport or industry.1 Livestock rearing 
for meat and dairy produce is a major source of emis�
sions, including methane from enteric fermentation and 
carbon dioxide as a result of land clearance for cattle 
farming.3 Polices that internalise the environmental 
costs of livestock production would reduce the con�
sumption of animal products. This would help stabilise 
the climate, but would also—by reducing the amount of 
saturated fat and meat in the diet—reduce the incidence 
of cardiovascular disease and bowel cancer.3 Similar 
policies on other foods might decrease the consumption 
of the carbon intensive fats and refined sugars that are 
helping to fuel the obesity pandemic.4
The transition to a low carbon transport system that 
involved more walking and cycling would substantially 
benefit health.5 Road traffic crashes account for 1.2 mil�
lion deaths worldwide each year and 10 times as many 
serious injuries. Their incidence is a function of the 
use of fossil fuels by the transport sector.6 After all, the 
kinetic energy that breaks bones and tears soft tissues 
comes from the chemical energy stored in the fuel tank, 
the burning of which emits carbon dioxide. Death rates 
for pedestrians and cyclists exhibit steep social gradi�
ents, and reducing traffic volumes and speeds would 
have important equity implications.7 Urban air pollu�
tion—much of which is related to transport—causes a 
further 800 000 premature deaths each year.5 Walking, 
cycling, or using public transport instead of travelling 
by car would reduce the use of energy from fossil fuels; 
it would also reduce traffic injuries and air pollution. By 
increasing physical activity it would tackle the output 
side of the personal energy balance equation, again 
with implications for obesity.
Improvements in the efficiency of home energy will 
reduce mortality and morbidity from the extremes of 
heat and cold and reduce the vulnerability of the poor 
to fluctuations in the price of energy.8 Greater use of 
renewable energy sources will also reduce urban air 
pollution. In generating electricity, the energy sources 
with the highest carbon dioxide emission profiles also 
have the greatest effect on air pollution and the inci�
dence of occupational injuries.9
Providing access to clean energy for the 2.4 billion 
people who use biomass fuels for cooking would reduce 
the burden of mortality and morbidity from indoor air 
pollution, and universal access to clean electricity could 
initiate a tidal wave of human creativity and accelerate 
the pace of human development.2 10
Like Tony Blair, Gordon Brown also welcomed the 
Stern review calling it “the most comprehensive analysis 
yet” and commenting that “above all environmental 
policy is economic policy.” Stern acknowledged that 
any positive effects of tackling climate change over and 
above those detailed in his review would strengthen the 
economic argument for stabilising the climate. The full 
extent of health benefits is only now coming to light.
Climate change, a globally important externality, is at 
least partly the result of leaving environmental impact 
out of economic decision making. To leave out health 
when considering the benefits of policies that tackle cli�
mate change would be a second serious omission. �nvi�       
ronmental policy is economic policy. It is also health 
policy. �conomists and health professionals must work 
together to ensure that the effects of environmental 
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Aspirin resistance in cardiovascular disease
Carries a worse prognosis, but may indicate pre-existing higher risk
Aspirin has clear benefits in cardiovascular disease. It 
reduces total mortality, cardiovascular mortality, and 
cardiovascular morbidity in people with cardiovascular 
disease or those at high risk of the disease; it is also 
cheap, relatively safe, and easy to use.1 So why does 
aspirin fail to work in some people who take it as pre�
scribed? Research on this clinical “resistance” to aspirin 
has tried to assess whether the effect on the in vitro acti�
vation of platelets depends only on the dose and type 
of antithrombotic agent given, or whether some people 
respond poorly (“resist”) to a specific drug, as some 
people do to specific antibiotics. In the accompanying 
systematic review, Krasopoulos and colleagues assess 
whether resistance to aspirin is related to cardiovascular 
outcomes in people with cardiovascular disease.2
To date, most research has focused on whether aspi�
rin resistance really exists, whether antiplatelet resist�
ance is specific to certain agents or classes of drug,3 and 
whether resistance carries a worse prognosis. Firstly, no 
accepted gold standard test to define aspirin resistance 
is available.4 This and other epidemiological consid�
erations have led some authors to argue that what has 
been dubbed resistance is just part of normal (Gaussian) 
variability in pharmacokinetics and pharmacodynam�
ics. Others admit that aspirin resistance exists but are 
doubtful about its prognostic importance.5 They think 
that a lack of response to aspirin could just be a proxy 
marker for more advanced pre�existing disease or less 
controlled traditional risk factors.
Krasopoulos and colleagues review analysed data 
from 20 studies and 2930 patients and found resistance 
to aspirin in 28% of people. Resistance was significantly 
more common in women and those with renal failure 
and was associated with a statistically and clinically sig�
nificant increase in the risk of death or adverse cardio�
vascular events, at least in univariate analysis. However, 
they found no association between the dose of aspirin or 
concomitant use of other antiplatelet agents and adverse 
events. The review has some limitations including use 
of fixed effect methods and lack of pooled multivariable 
adjusted estimates. A similar review recently came to 
the same conclusions, however, confirming the external 
validity of Krasopoulos and colleagues’ review.6
Despite this work several questions remain. We don’t 
know whether aspirin resistance is a true abnormal 
response or whether it reflects normal variability in drug 
activity. We also aren’t clear whether aspirin resistance 
has a negative prognostic effect independent of more 
traditional risk factors, such as diabetes or obesity.5 If 
aspirin resistance is an abnormal response that results 
in worse prognosis then what can clinicians do? We sug�
gest that when aspirin resistance is suspected patients 
should be screened using available tests. Management 
of patients with aspirin resistance should include a 
comprehensive appraisal of thrombotic and bleeding 
risks, the likelihood of non�adherence to treatment, and 
access to other antiplatelet agents. On the basis of this 
assessment, several strategies can then be proposed. 
These include adding another antiplatelet agent (for 
people at high thrombotic risk and low bleeding risk), 
substituting aspirin with the more effective clopidog�
rel (for people at intermediate thrombotic risk and 
low bleeding risk), increasing the dose of aspirin (for 
example, to 325 mg/day in people at mildly increased 
thrombotic risk and low to intermediate bleeding risk), 
or continuing with the same antiplatelet regimen (for 
everyone at high bleeding risk).
The problem in finding truly scientific answers to 
the effectiveness of these strategies lies in the lack 
of randomised controlled clinical trials. This will 
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policies on health and development are quantified and 
included in the economic models that inform our collec�
tive response to the threat from climate change.
It would not be the first time that environmental 
policy had substantial benefits for health. Two hundred 
years ago the streets of London were awash with sew�
age. In 1858 the smell from the Thames was so strong 
that MPs declared the House of Commons “unus�
able.”11 Infectious disease was a deadly scourge, but 
it was the “great stink” of 1858 that helped secure the 
funds needed to sort out London’s sewage. Policy on 
sewage did more to improve the health of Londoners 
than any health policy that century. Indeed, in a recent 
BMJ poll, sanitation was voted the greatest medical 
advance in the past 166 years.12 Could tackling climate 
be the next great medical advance?
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